Updated August 16, 2026. Full-year FY2026 appropriations for NIH are enacted, not pending. If your office is still operating on guidance describing NIH as under a continuing resolution, that guidance is out of date — the continuing-resolution period ended in early February 2026, and this piece walks through what the enacted funding level actually changes for award timing, payline expectations, and Notice of Award (NOA) processing for the rest of the fiscal year.
Full-Year FY2026 Appropriations Are Enacted, Not a Continuing Resolution
NIH began fiscal year 2026 under a continuing resolution (Notice NOT-OD-26-011, issued November 21, 2025 under P.L. 119-37), which funded the agency through January 30, 2026 at capped, prior-year-based rates. A brief lapse in appropriations followed at the end of January, covered by subsequent NIH reopening notices. That period is over. Congress passed, and the President signed, the Further Consolidated Appropriations Act, 2026 (P.L. 119-75) on February 3, 2026, enacting full-year Labor-HHS-Education appropriations for the remainder of FY2026.
Netted across P.L. 119-75 and a companion FY2026 measure, P.L. 119-74, NIH’s total FY2026 program level is approximately $47.493 billion — about $458 million, or roughly 1.0 percent, above the final FY2025 level, per the Congressional Research Service’s NIH funding tracker (CRS Report R43341, “National Institutes of Health (NIH) Funding: FY1996–FY2026”). That is a modest real increase, not the roughly 40 percent reduction the administration’s FY2026 budget request had proposed, and it leaves NIH’s 27-institute-and-center structure intact rather than the eight-institute consolidation that request also sought. For the fuller proposed-vs-enacted picture, including the terminations and litigation that ran in parallel with the appropriations fight, see CASRAI’s NIH funding cuts in 2026 landscape piece.
Two provisions in the enacted law matter specifically to research administration offices:
- The statute bars NIH from imposing the 15 percent flat indirect-cost (F&A) rate cap it had attempted via Notice NOT-OD-25-068 — a threat that had already been enjoined in litigation for most institutions, and is now foreclosed at the legislative level as well. See how the indirect cost cap litigation ended for the fuller history.
- Congress allowed NIH to continue a revised multi-year, lump-sum funding approach for certain awards (notably R01s) rather than reverting to the traditional annual-increment model. Reporting on the deal ties this to several thousand fewer new individual-investigator awards than the prior funding structure would have produced, even though the topline dollar figure is flat to slightly up. See NIH’s multiyear lump-sum funding for R01s and the FY2026 appropriations cap for the award-count mechanics.
What Resolving the CR Uncertainty Actually Changes for RA Offices
A continuing resolution keeps an agency funded, but usually at a flat or capped rate tied to the prior year, without the specific programmatic direction a full-year bill carries — and it leaves open the risk of a lapse if Congress doesn’t act again before the CR’s own expiration date. Institutions typically responded to the FY2026 CR period the way they respond to any CR: conservative institutional guidance on new commitments, caution around no-cost extensions and supplement requests that assume full-year funding, and closer tracking of NIH’s own notices for lapse contingency plans.
With P.L. 119-75 enacted, that specific uncertainty is closed for FY2026. Institutes and Centers (ICs) now have a known, full-year appropriation to plan against rather than operating notice-to-notice. For research offices, that means the CR-era caution around FY2026 commitments is no longer warranted on appropriations grounds — though, as the sections below cover, “the money is appropriated” and “award decisions will look like a normal year” are not the same claim, because NIH changed how it makes some of those decisions independently of the budget fight.
Award Timing and NOA Processing: What to Expect Through the Rest of FY2026
Two mechanical effects follow directly from a mid-year full-year enactment:
- A mid-year catch-up in Notice of Award (NOA) issuance. Awards and non-competing continuations that were held during the CR and lapse period, funded only at interim or partial levels (or not funded at all pending the full-year bill), are now eligible to be finalized against the enacted appropriation. Expect NOA issuance to be uneven this fiscal year — a lighter early period followed by a denser stretch of awards and supplements processed after February 3 — rather than the roughly even monthly pace a full-year-from-October-1 appropriation would produce.
- Payment processing timeliness under scrutiny. Report language accompanying the FY2026 Labor-HHS bill directs HHS to process grant disbursements — through the Payment Management System NIH grantees already draw from — within 5 business days except under extraordinary circumstances, with advance notice to Congress required before any restriction on that timeline. This is committee report language, not a new statutory NIH payment mechanism, and it applies to HHS broadly rather than naming NIH specifically. See CASRAI’s full breakdown of the FY2026 5-business-day grant payment rule for what it does and doesn’t guarantee.
For a full picture of where NOA timing sits in NIH’s broader annual cycle — receipt dates, study section, council rounds, and award issuance — see CASRAI’s NIH grant cycle timeline guide.
Payline Expectations: Don’t Assume the Old Percentile Model
This is the part most likely to catch research offices off guard: resolving the appropriations uncertainty does not mean paylines return to their traditional form. Separately from the budget fight, NIH announced a Unified Funding Strategy, effective for the January 2026 Council round, under which Institutes and Centers are directed not to rely on published percentile paylines when making pay decisions. Instead, ICs weigh percentile scores against their own priorities, strategic plans, and budgets on a more case-by-case basis. Around half of NIH’s ICs had published traditional paylines before this shift; many IC webpages that used to carry payline-style guidance now redirect to a central NIH funding-decisions page instead.
Practically, that means a known, adequate full-year appropriation does not translate into a single predictable percentile cutoff the way it might have in earlier fiscal years. Applicants and research offices should not treat “the budget is settled” as equivalent to “the old payline for my IC will apply.” CASRAI’s cross-institute FY2026 payline reference tracks what each IC currently publishes, or doesn’t, under the new approach, and links out to institute-specific pages (for example, NIH Payline, NIH Priority Score) for the underlying mechanics of how percentile scores are generated and compared.
What Research Administration Offices Should Do Now
- Update internal guidance that still references CR-era caution. Any standing institutional memo advising extra scrutiny on FY2026 commitments because “the budget isn’t final” needs a refresh — the budget is final for FY2026 as of February 3, 2026.
- Expect, and plan cash-flow around, an uneven NOA cadence rather than assuming awards delayed by the CR period simply vanished — most are catching up against the enacted appropriation, not cancelled.
- Stop quoting single-number paylines to PIs without a source check. Direct investigators to the specific IC’s current funding-decisions page (or CASRAI’s cross-institute reference) rather than a remembered prior-year percentile.
- Watch the multiyear lump-sum award mechanics for R01s and similar mechanisms specifically — the enacted bill’s flat-to-slightly-up topline doesn’t mean flat new-award counts; the shift to lump-sum funding for some awards changes how many new awards a given appropriation produces.
- Note that FY2026 is closed as an appropriations question — the open question now is FY2027, which is a separate, still-unresolved continuing-resolution fight (the House and Senate had passed two different, unreconciled stopgap bills as of mid-August 2026). Don’t conflate the two when briefing leadership.
Frequently Asked Questions
Is NIH currently operating under a continuing resolution?
No, not for FY2026. Full-year FY2026 Labor-HHS-Education appropriations were enacted February 3, 2026 via P.L. 119-75. A separate continuing-resolution fight over FY2027 funding (which begins October 1, 2026) was still unresolved between the House and Senate as of mid-August 2026 — that is a distinct, later question from FY2026’s status.
What is NIH funded at for FY2026?
Approximately $47.493 billion across NIH’s institutes and centers, roughly 1.0 percent above the final FY2025 level, per the Congressional Research Service’s NIH appropriations tracking report (CRS R43341).
Does the enacted appropriation mean my institute’s payline is back to normal?
Not necessarily. NIH’s move away from published percentile paylines under its Unified Funding Strategy is a separate policy change from the appropriations process, effective for the January 2026 Council round. Check the specific IC’s current funding-decisions guidance rather than assuming a resolved budget restores a traditional payline.
Why are Notices of Award arriving unevenly this fiscal year?
Awards and continuations held back during the CR and lapse period are being finalized against the enacted appropriation now that it exists, producing a denser stretch of NOA activity after February 3, 2026 rather than an even month-by-month pace.
